Top Markets
#1 DogBull DogBull +54.95%
#2 Siren Siren +30.68%
#3 OriginTrail OriginTrail +21.40%
#4 龙虾 (Lobster) 龙虾 (Lobster) +10.93%
#5 Ethena Staked ENA Ethena Staked ENA +10.57%
#6 Cysic Cysic +8.95%
#7 Stargate Finance Stargate Finance +8.71%
#8 COTI COTI +7.88%
#9 Ether.fi Ether.fi +7.19%
#10 Collect on Fanable Collect on Fanable +7.11%
Coin of the day
DogBull DogBull
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Acrivon Therapeutics, Inc. Common Stock Acrivon Therapeutics, Inc. Common Stock

Acrivon Therapeutics, Inc. Common Stock

ACRV
Classifica tra le azioni #22054
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical... Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.
Prezzo delle azioni
$2.23
Ultima sincronizzazione: 2026-08-21
Capitalizzazione di mercato
$95.23M
Variazione (1 giorno)
1.14%
Variazione (1 anno)
63.60%
Paese
US
Scambia Acrivon Therapeutics, Inc. Common Stock (ACRV)

Categoria

Healthcare
Margine operativo per Acrivon Therapeutics, Inc. Common Stock (ACRV)
Margine operativo al 2026 TTM: 0.00%
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Acrivon Therapeutics, Inc. Common Stock, il margine operativo attuale (TTM) è 0.00%. Alla fine del 2026, il margine operativo era 0.00%.
Storico del margine operativo per Acrivon Therapeutics, Inc. Common Stock da 2026 a 2026
Margine operativo alla fine di ogni anno
Anno Margine Operativo Cambia
Non abbastanza dati per le date fornite.
Margine operativo per aziende simili o concorrenti
Azienda Margine Operativo Differenza del margine operativo Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
-149.01% -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.72% -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
Cos'è l'Margine operativo di un'azienda?
L'Margine operativo è un indicatore chiave per valutare la redditività di un'azienda. Margini operativi più elevati sono generalmente preferibili poiché indicano che l'azienda riesce a vendere i propri prodotti o servizi a un prezzo significativamente superiore rispetto ai costi di produzione. Si calcola dividendo gli utili per i ricavi.